Author Archives: BPI Staff

Astrea licenses Avacta’s Affimer reagent technology

Gamma Biosciences’ bioseparation business Astrea will use the Affimer technology to expand its range of ligand discovery and development capabilities. Avacta Group’s Affimer reagents are small proteins that have a binding surface that can be tailored to capture a target molecule of interest out of complex mixtures encountered in biomanufacturing. “The Affimer reagent technology was originally developed at the MRC Cancer Unit in Cambridge UK for proteomics applications and was acquired by Avacta in 2012,” Alastair Smith, CEO of Avacta…

Sanofi shells out $1.1bn for immunology Mab maker Kymab

Sanofi will gain global rights to KY1005 and a monoclonal antibody discovery and development platform through the addition of Kymab. French pharma giant Sanofi is paying $1.1 billion upfront for Cambridge, UK-based biotech Kymab with a further $350 million depending on potential milestones. The deal brings the fully humanized monoclonal antibody KY1005 to Sanofi’s pipeline, along with four other early clinical and preclinical candidates. According to the firm, the candidate targets immune system regulator OX40-Ligand, “blocking inappropriate activation and proliferation…

The next frontier of CAR-T cell therapies: Allogeneic workflows

The development of CAR-T cell therapies provides treatment options for some of the most vulnerable cancer patients, giving them a fighting chance to battle their diagnoses if they’re eligible. Researchers and organizations continue to work diligently to optimize the manufacturing process to develop safe and effective CAR-T cell therapies as efficiently as possible, with the hope that one day they can be manufactured at a lower cost and made available to any patient who could benefit from them. Personalized therapies…

Natural killer deal: Sanofi buying Kiadis for $358m

Once the deal goes through, the French pharma giant will add an allogeneic natural killer (NK) cell therapy platform to its immune-oncology capabilities. In cell therapy development, industry has seen some success with T-cells, most notably in the approvals of the chimeric antigen receptor T-cell therapies Kymriah and Yescarta. T cells work by spurring patients’ adaptive immune system, which learns to remember threats and eliminates them when they return. However, NK cells, which are part of our innate immune system,…

Podcast: The impact of COVID-19 on the pharma and bio supply chain

Bioprocess Insider editor Dan Stanton joins an industry panel to discuss supply chain concerns stemming from the ongoing coronavirus crisis. Listen to the podcast now. Brought to you by international pharmaceutical content, digital and design agency ramarketing, the Molecule to Market podcast takes a listen to the contract outsourcing space with industry insights direct from the brains of the people that make the headlines. In this special episode, one of the headline writers – Bioprocess Insider founder and editor Dan…

CellGenix: Serum-free medium offers faster T-cell therapy manufacturing

Freiburg, Germany-based CellGenix says its T-cell medium – CellGenix TCM – offers a serum-free and xeno-free alternative for rapid expansion of functional human T-cells. Due to stable glutamine in the formulation, the medium is ready-to-use for T-cell cultures without the need for supplementation with human serum or glutamine. Many current T-cell therapy protocols rely on the addition of human serum. Eliminating the use of human serum will reduce the failure rate in your manufacturing process due to the high lot-to-lot…

Trump’s ‘reckless’ drug pricing Executive Order threatens innovation, BIO chief

The US is doing more in the COVID-19 space than anywhere in the world due to the strength of its innovative ecosystem, says Michelle McMurry-Heath, head of trade group BIO. But such innovation is under threat due to “reckless” orders coming out of the White House. As part of an exclusive interview filmed for Xconomy’s Xcelerate’s Keynote Series at Biotech Week Boston next week, Michelle McMurry-Heath, president & CEO of life sciences advocacy group Biotechnology Innovation Organization (BIO), criticized Executive…

Advanced therapy news: RoslinCT, Marker, Freeline to establish facilities

As the surge in cell and gene therapies entering and progressing through the clinic continues, we highlight manufacturing plans from Marker Therapeutics, Freeline, and CDMO RoslinCT. First up in this cGMP manufacturing investment roundup is clinical-stage immuno-oncology company Marker Therapeutics, which has announced plans to lease a facility in Houston, Texas The 48,500 square-foot plant, expected to be operational in 2021, will support the firm’s T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. “We are…

Repligen boosting single-use portfolio with Engineered Molding Technology buy

Repligen will add silicone single-use consumables and components for bioprocessing functions through the addition of Engineered Molding Technology (EMT). The size of the deal has not been divulged, but Repligen will expand its single-use filtration and chromatography system component portfolio with custom molded and over-molded connectors and silicone tubing products. “The acquisition of EMT expands our line of single-use ProConne® flow paths, streamlines our supply chain for ATF, and gives us more flexibility as we scale and expand our single-use…